Hence, given the high rate of relapse and primary resistance of AML patients, there is a compelling rationale to combine DNA damaging standard AML chemotherapy and HMAs, with inhibitors of the DDR master regulators ATR, ATM, DNA-PK, and their DDR downstream substrates, to boost therapeutic efficacy and overcome therapy resistance. Here, ATM is linked to acute myeloid leukemia.